House Energy & Commerce Democratic Leadership Seeks Hearing On Part D Waste And Fraud
This article was originally published in The Pink Sheet Daily
Request follows HHS Office of Inspector General report that shows plans underestimated rebates in 2008, which led to higher beneficiary premiums.
You may also be interested in...
CMS estimates that removing antidepressants, antipsychotics and immunosuppressants from “protected class” status in Medicare Part D could save $720 million between 2016 and 2019.
Increasing Part D premiums have caught the eye of Rep. Henry Waxman, who sees them as further evidence that HHS would do a better job of negotiating drug prices for Part D than the private sector
Twenty-seven percent of the various drug products used by Medicare Part D enrollees are subject to manufacturer rebates that reduce their price, according to a survey of the leading 12 Part D insurance providers